Kura Oncology (KURA)
8.74
0.00 (0.00%)
Upcoming Events
Latest Headlines
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 5, 2026 7:30 AM - Globe NewsWire
Form 4 Kura Oncology, Inc. For: Jun 04 Filed by: Hasnain Faheem
June 4, 2026 6:30 PM - SEC Filing
Form 4 Kura Oncology, Inc. For: Jun 04 Filed by: Parks Diane L.
June 4, 2026 6:30 PM - SEC Filing
Form 4 Kura Oncology, Inc. For: Jun 04 Filed by: VASCONCELLES MICHAEL
June 4, 2026 6:30 PM - SEC Filing
Form 4 Kura Oncology, Inc. For: Jun 04 Filed by: Collins Helen Louise
June 4, 2026 6:30 PM - SEC Filing
Form 4 Kura Oncology, Inc. For: Jun 04 Filed by: Szela Mary T
June 4, 2026 6:30 PM - SEC Filing
Form 4 Kura Oncology, Inc. For: Jun 04 Filed by: Malley Thomas
June 4, 2026 6:30 PM - SEC Filing
Form 4 Kura Oncology, Inc. For: Jun 04 Filed by: SCHAFER CAROL
June 4, 2026 6:30 PM - SEC Filing
Form S-8 Kura Oncology, Inc.
June 4, 2026 5:25 PM - SEC Filing
Form 8-K Kura Oncology, Inc. For: Jun 04
June 4, 2026 4:05 PM - SEC Filing
Kura Oncology (KURA) Reiterated at Overweight by Cantor Fitzgerald
June 4, 2026 7:07 AM - StreetInsider
Kura Oncology (KURA) Reiterated at Market Outperform by Citizens
June 4, 2026 5:25 AM - StreetInsider
Kura Oncology reports clinical trial data for cancer drug darlifarnib
June 3, 2026 6:55 AM - StreetInsider
Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy
June 3, 2026 6:53 AM - Globe NewsWire
Kura Oncology publishes ziftomenib combination study in Blood journal
June 2, 2026 8:33 AM - StreetInsider
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
June 2, 2026 8:32 AM - Globe NewsWire
Kura Oncology (KURA) Reiterated at Market Outperform by Citizens on FIT-001 Data Preview
May 28, 2026 5:21 AM - StreetInsider
Form DEFA14A Kura Oncology, Inc.
May 26, 2026 4:42 PM - SEC Filing
KURA reports tumor shrinkage in 77% of patients in drug combination trial
May 26, 2026 6:02 AM - StreetInsider
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
May 26, 2026 6:02 AM - Globe NewsWire
Form 4 Kura Oncology, Inc. For: May 21 Filed by: Powl Brian T.
May 22, 2026 4:06 PM - SEC Filing
Form 144 Kura Oncology, Inc. Filed by: Powl Brian T.
May 21, 2026 4:32 PM - SEC Filing
Form 4 Kura Oncology, Inc. For: May 19 Filed by: Powl Brian T.
May 20, 2026 4:06 PM - SEC Filing
Form 4 Kura Oncology, Inc. For: May 18 Filed by: Bair Teresa Brophy
May 20, 2026 4:06 PM - SEC Filing
Form 4 Kura Oncology, Inc. For: May 19 Filed by: FORD KATHLEEN
May 20, 2026 4:05 PM - SEC Filing
Form 144 Kura Oncology, Inc. Filed by: FORD KATHLEEN
May 19, 2026 4:39 PM - SEC Filing
Form 144 Kura Oncology, Inc. Filed by: Powl Brian T.
May 19, 2026 4:38 PM - SEC Filing
Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit
May 19, 2026 4:02 PM - Globe NewsWire
Form 144 Kura Oncology, Inc. Filed by: Bair Teresa Brophy
May 18, 2026 4:32 PM - SEC Filing
Form SCHEDULE 13G/A Kura Oncology, Inc. Filed by: ARMISTICE CAPITAL, LLC
May 15, 2026 11:26 AM - SEC Filing
Kura Oncology (KURA) Reiterated at Market Outperform by Citizens After Q1 Results
May 13, 2026 5:48 AM - StreetInsider
Form 10-Q Kura Oncology, Inc. For: Mar 31
May 12, 2026 4:16 PM - SEC Filing
Form 8-K Kura Oncology, Inc. For: May 12
May 12, 2026 4:11 PM - SEC Filing
Kura Oncology (KURA) Reports In-Line Q1 EPS
May 12, 2026 4:02 PM - StreetInsider
Kura Oncology Reports First Quarter 2026 Financial Results
May 12, 2026 4:02 PM - Globe NewsWire
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
May 12, 2026 9:41 AM - StreetInsider
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
May 12, 2026 9:40 AM - Globe NewsWire
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
May 6, 2026 7:30 AM - Globe NewsWire
Kura Oncology to Report First Quarter 2026 Financial Results
May 5, 2026 7:30 AM - Globe NewsWire
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 4, 2026 7:30 AM - Globe NewsWire
Form SCHEDULE 13G Kura Oncology, Inc. Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 30, 2026 11:01 AM - SEC Filing
Kyowa Kirin begins phase 2 trial of ziftomenib in Japan for AML
April 24, 2026 8:00 AM - StreetInsider
Kura Oncology reports darlifarnib plus cabozantinib shows activity in kidney cancer
April 17, 2026 6:00 AM - StreetInsider
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib
April 17, 2026 6:00 AM - Globe NewsWire
Lake Street Starts Kura Oncology (KURA) at Buy
April 14, 2026 7:24 AM - StreetInsider
Form ARS Kura Oncology, Inc. For: Dec 31
April 10, 2026 4:45 PM - SEC Filing
Form DEFA14A Kura Oncology, Inc.
April 10, 2026 4:35 PM - SEC Filing
Form DEF 14A Kura Oncology, Inc. For: Jun 04
April 10, 2026 4:25 PM - SEC Filing
Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026
April 9, 2026 7:30 AM - Globe NewsWire
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 3, 2026 7:30 AM - Globe NewsWire
Form SCHEDULE 13G/A Kura Oncology, Inc. Filed by: VANGUARD GROUP INC
March 27, 2026 10:21 AM - SEC Filing
Form 4 Kura Oncology, Inc. For: Mar 23 Filed by: WILSON TROY EDWARD
March 25, 2026 9:00 AM - SEC Filing
Kura Oncology (KURA) PT Lowered to $25 at Mizuho
March 24, 2026 10:56 AM - StreetInsider
Form 4 Kura Oncology, Inc. For: Mar 18 Filed by: Malley Thomas
March 20, 2026 9:10 AM - SEC Filing
Kura Oncology (KURA) PT Lowered to $15 at UBS
March 13, 2026 9:10 AM - StreetInsider
Full Article List
